anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The current invention concerns the use of PIP or S100A8 for the generation of regulatory T cells. The current invention provides a method of generating regulatory T cells by contacting immature DC with PIP or S100A8 to produce tolerogenic DC and further contacting naive T cells to the tolerogenic DC to produce regulatory T cells. The invention also concerns PIP protein where immature DC contacted with PIP produce tolerogenic DC that induce conversion of naive T-cells into regulatory T cells. The invention also concerns S100A8 protein where immature DC contacted with S100A8 produce tolerogenic DC that induce conversion of naive T-cells into regulatory T cells. The invention also provides methods for identification of factors secreted by iNKT cells that induce conversion of immature DC into tolerogenic DC. The subject invention also concerns using regulatory Tcells for treatment and/or management of cancer or the diseases of the immune system.
Vaccination is one of the greatest public health achievements of the 20th century, with a tremendous impact in the prevention and control of diseases. However, the recent reemergence of vaccine-preventable diseases calls for a need to evaluate current vaccination practices and disparities in vaccination between high-income countries and low-and-middle-income countries. There are massive deficits in vaccine availability and coverage in resource-constrained settings. Therefore, this perspective seeks to highlight the reemergence of vaccine-preventable diseases in Africa within the lens of health equity and offer recommendations on how the continent should be prepared to deal with the myriad of its health systems challenges. Among the notable factors contributing to the reemergence, stand health inequities affecting vaccine availability and the dynamic vaccine hesitancy. Strengthening health systems and addressing health inequities could prove useful in halting the reemergence of vaccine-preventable diseases.
The intervention will include all together 12 sessions, each being 45 minutes, for a total of 3 weeks. The intervention will include: 4 treatments in the area of memory and attention, 4 treatments in the area of problem solving, 4 treatments in the area of planning and analysing.
Risperidone tablets given during the screening period to check for sensitivity. RBP-7000 administered as a 90 mg subcutaneous injection on Days 1 and 29 for a total of two injections.
The invention belongs to the technical field of medicine and discloses a liquid medicine for relieving itching of various skin diseases, and a preparation method thereof in particular. The liquid medicine for relieving itching of various skin diseases is prepared by the following materials: sulfur, borneol, camphor, pricklyash peel, sessile stemona root, belvedere fruit, halcinonide solution, and medicinal alcohol B. The preparation method comprises the following steps: after the six medicines of sulfur, borneol, camphor, pricklyash peel, sessile stemona root and Belvedere fruit are ground into powder, halcinonide liquid is added then, and finally the obtained mixture is added into the medical alcohol B together for dipping for 24 to 48 hours. The materials of the invention are easily obtained and the preparation method is simple. The liquid medicine is preferentially prepared into a lotion and arrives the affected part directly to exert the effects of disinsection, rheumatism and itching relief, and sterilization; simultaneously the liquid medicine can stimulate the skin and improve the microcirculation and the regulation functions of human bodies, thereby removing pathological changes. A plurality of clinic treatment effects prove that the liquid medicine has wide application range, the cure rate of more than 95 percent, and extremely good effects.
FIELD: medical engineering. SUBSTANCE: device has canal for receiving single capsule in preferred oriented position, container for holding loaded capsule stock and inclined member surface guiding capsule movement towards the canal when the device is oriented so that the canal is directed vertically downward relative to the container. When selecting appropriate inclined member tilt angle, canal diameter and container diameter, high probability of single capsule being loaded into the canal used for maintaining dosed release is achieved, when the device is turned for placing the canal used for maintaining dosed release below the loaded capsule stock. The device is especially useful when used in a device for dosing dry medicament having an additional unit beside one for orientation capsule, being a chamber for receiving the capsules from the canal for dosing medicament release, means for piercing capsule ends and sucking air through the capsule for capturing the medicament. EFFECT: enhanced effectiveness in orienting capsules from arbitrary position to a required one and enabling in this way dosed output. 16 cl, 5 dwg, 1 tbl
NEW MATERIAL:A tetronolide expressed by formula I (R1 and R2 are H or acyl; R3 is H, acyl or tetronitrose of formula II) and a salt thereof. EXAMPLE:17-O-Tetronitrosyltetronolide expressed by formula III. USE:An antimicrobial agent, an antitumor agent and a synthetic intermediate therefore, administered intravenously or intraperitoneally in a dose of 0.2-0.5mg/kg/day. PROCESS:A microorganism, e.g. Micromonospora chalcea XY11091 strain (FERM-P No.4458, NRRL11289), capable of producing a tetronolide compound expressed by formula IV is cultivated in a untrient culture medium, and the compound expressed by formula IV in the compound expressed by formula I in which R1 and R2 are H respectively is obtained from the culture. The hydroxyl group at the 9 or 21 position of the compound expressed by formula IV is acylated by the chemical synthetic method if necessary to give the remaining compound expressed by formula I.
CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides mixed with Montanide ISA 51 Patients will be vaccinated once a week until patients develop progressive disease or unacceptable toxicity. On each vaccination day, CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides (0.5, 1 or 2mg of each peptide) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
BACKGROUND: Ampulla of Vater carcinoma (AVC) stage T3 was subdivided according to the degree of pancreatic invasion into T3a (≤ 0.5 cm) and T3b (> 0.5 cm) by the 8th edition of the Union for International Cancer Control (UICC)/American Joint Committee on Cancer (AJCC) cancer staging system. However, the differences in clinicopathological features and survival outcomes between the two categories have not been well discussed.
PATIENTS AND METHODS: We retrospectively analyzed 133 consecutive patients who underwent pancreatoduodenectomy for AVC at our institution between 2002 and 2020. Clinicopathological features and survival outcomes of patients with AVC were analyzed, with a focus on the depth of pancreatic invasion. In addition, the survival outcomes of patients with T3 AVC were compared with those of patients with resectable pancreatic head carcinoma (R-PhC) who underwent pancreatoduodenectomy during the same period.
RESULTS: The overall survival (OS) in patients with T3b AVC (n = 12) was significantly worse than that in patients with T3a AVC (n = 39) [median survival time (MST) 9.2 vs. 74.5 months, p < 0.001). A multivariate analysis identified T3b tumor (hazard ratio 5.64, p = 0.009) as an independent prognostic factor. The OS of patients with T3a AVC was significantly better than that of patients with R-PhC who received adjuvant chemotherapy (n = 276, MST 35.0 months, p = 0.007). In contrast, the OS of patients with T3b AVC tended to be worse than that of patients with R-PhC managed without adjuvant chemotherapy, although this difference was not statistically significant (n = 163; MST, 17.5; p = 0.140).
CONCLUSIONS: AVC with > 0.5 cm invasion into the pancreas was associated with poor survival and represented advanced tumor progression to systemic disease.
Netherton Syndrome is a serious skin disorder caused by damage in a gene called SPINK5. This gene controls the formation of a protein called LEKTI, which important for skin barrier function. LEKTI inhibits certain enzymes (serine proteinases) in the outermost layer of the skin (epidermis). The function of the serine proteinases is to break down the intracellular cement that holds together the horny cells in the epidermis, in order for the skin to be able to shed cells (known as cell desquamation). LEKTI deficiency leads to an uninhibited desquamation of horny cells, and as a result the skin becomes red and scaly. The barrier function of the skin is also affected. The permeability of the skin increases, and its capacity to bind water decreases, which causes dryness. The thinness of the barrier also results in over absorption of chemicals, for example topical medical treatments. Historically one in ten infants dies before their first birthday. Currently there are no proven treatments to cure this condition.

The investigators have been developing a gene therapy approach to treat this disorder. The investigators have used a disabled virus (vector) to carry a functional copy of the SPINK5 gene into skin stem cells. Proof-of-principle experiments have shown the investigators can restore almost normal shape and size of the upper layer of the skin in skin grafts grown in the lab. Even if only a small number of cells are genetically modified to carry the corrected SPINK5 gene, there seems to be a correction over a wide area of the graft.

In this trial the investigators propose grafting of autologous epidermal sheets generated from genetically modified skin stem cells for the treatment of patients with Netherton Syndrome. The investigators anticipate production and release of LEKTI protein from even a small patch of skin will be beneficial.
FIELD: pharmacy. SUBSTANCE: invention relates to preparing sanguiritrin from plume poppy (Macleya, Bocconia, lat. ) species above-ground parts. Extraction of vegetable raw is carried out with aliphatic alcohol (for example, aqueous ethanol) in the presence of ammonium hydroxide. Organic solvent is removed from extract under vacuum, an aqueous vat residue is treated with hydrophobic organic solvent (for example, methylene chloride, dichloroethane, chloroform, toluene, ethyl acetate). The end alkaloid bisulfate is precipitated by treatment of an aqueous phase with diluted sulfuric acid. Technical product is separated, washed with organic solvent that is used at the stage of liquid-phase extraction and then with acetone, dried and purified by the known method. Additional stage involves washing an organic phase with water up to neutral reaction before the precipitation stage of the end product with sulfuric acid. EFFECT: improved method of preparing. 3 tbl
PURPOSE: A hydrophilic nanoparticle, a colloidal solution, and an MRI(Magnetic Resonance Imaging) contrast agent containing the same are provided to be applied to a bio-medical field and to ensure excellent dispersion stability. CONSTITUTION: A hydrophilic nanoparticle with a modified surface contains monosaccharide phosphoric acid or a derivative thereof attached on the surface of inorganic particles. The size of the hydrophilic nanoparticle is 1-200 nm. The organic particle is a metal, metal chalcogenide, metal oxide, a magnetic material, a magnetic alloy material, a semi-conductive material, or a multicomponent hybrid structure. The monosaccharide phosphoric acid is glucose-6-phosphate, fructose-6-phosphate, or mannose- 6-phosphate. A colloidal solution contains the hydrophilic nanoparticles dispersed in water. A contrast agent contains the colloidal solution. The contrast agent is an MRI T1 contrast agent or an MRI T2 contrast agent.
FIELD: medicine. ^ SUBSTANCE: treatment of oropharyngeal squamous cell carcinoma is ensured by drop-by-drop introduction of cetuximab 400 mg/m2 for the first day of the first week. Then from the first day of the second week, radiation therapy of large fractions 4 Gy is combined with introduction of cisplatin 30 mg for 3 days running. On the first day of the second to the fifth week, cetuximab 250 mg/m2 is introduced drop-by-drop. Further, a dose of radiation therapy is 2 Gy once a day, 5 times a week to total basic dose 30-40 Gy. In 2 weeks, the course is performed again to total basic dose 70 Gy according to the same scheme. ^ EFFECT: method allows increasing rate and degree of primary tumour regress, suppressing sub-clinical disseminated metastases, ensuring maximum anticancer effect without injuring normal tissue cells, enables preserving organ functions, increasing a number of organ-saving surgeries, improving quality of life of the patients, reducing invalidisation. ^ 2 ex
Participants will consume a meal standardised to contain 50 g of available carbohydrates. Sample Will be consumed together with 250 mL of water, within 10-15 minutes.
The high morbidity and mortality associated with both pandemic and seasonal influenza and the threat of new potentially pandemic strains emerging makes influenza an important infectious disease and public health problem. Public health agencies must continue attempts to reduce the public health impact of this important virus.

Currently, influenza vaccination is the cornerstone of prophylaxis and the most effective method available to reduce the impact of influenza on the population. Current vaccines target the major surface protein, hemagglutinin (HA), and are standardized by stimulation of serum anti-HA antibodies as the primary correlate of protection. Measurements of serum antibodies to HA have become the gold standard for evaluating vaccines. The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) both define protective titers as a hemagglutination inhibition (HAI) titer of greater than or equal to 40. Recent vaccine effectiveness has been limited and, in some populations, estimated at as low as 10%. Improved methods of vaccination must be developed, but limited information regarding the true correlates of protection is available. Correlates of protection in the systemic circulation may be less informative than those located in the nasopharyngeal mucosa, which is the site of exposure to and infection with influenza virus.

This study is designed to characterize the mucosal and systemic immunologic correlates of protection from influenza infection in persons vaccinated and unvaccinated against influenza. Half of participants will receive current licensed quadrivalent inactivated influenza vaccine (IIV) administered via the intramuscular (IM) route at the standard dose, prior to challenge with influenza virus. The other half will receive no vaccination prior to challenge. Immunologic response and clinical outcomes in the human challenge model will be determined to characterize the two cohorts. In the vaccinated cohort, mucosal and systemic immune responses induced by IM administration of quadrivalent IIV will also be carefully explored. The thoughtful study of mucosal immunity to influenza is expected to identify novel correlates of protection. By administering quadrivalent IIV and then infecting participants with human challenge virus, we can evaluate in detail the immunologic responses after immunization and subsequent virus exposure. This controlled setting offers the ideal environment to query these responses and to identify targets of mucosal stimulation for future vaccine strategies. In addition, the detailed characterization of the mucosal and systemic immune responses after vaccination and challenge will represent a true advance in understanding influenza immunity.
PURPOSE: To obtain a preventive for an infectious sexually transmitted disease to be used for bringing it into contact with mucosa, comprising an active ingredient for sealing MST-transmitting viruses and bacteria and a substance for controlling the permeation of the active ingredient through mucosa. CONSTITUTION: This preventive comprises at least one active ingredient (e.g. cholate) for sealing MST-transmitting viruses, bacteria a component (e.g. filmogen to be bonded to the active ingredient to form a membrane) for controlling the permeation of the active ingredient through mucosa, further a dispersant (e.g. silicone-based compound having inhibitory action on permeation) and a medicinal vehicle suitable for local administration. The medicine is optionally mixed with a spermicide. The medicine is used together with a vaginal tampon having a small channel playing a role of at least insertion and extraction and protects a local part of a female vagina having high degree of injection.
The standard method of repair for facial lacerations is to close such wounds with non-absorbable sutures. Recently, topical skin adhesives such as n-butyl-2-cyanoacrylate and 2-octyl cyanoacrylate have been used more frequently as these have been shown to be a faster and less painful way to close superficial facial lacerations. However, lacerations that are deeper, gaping or occurring along lines of excessive tension, such as the chin, still need sutures for repair. Non-absorbable sutures have to be taken out at 4-7 days. This involves another physician visit, parental absence from work, and children who need to be taken out of school or daycare for a simple suture removal.

In Part Iof the study, we were able to demonstrate non-inferiority of absorbable sutures to nylon sutures. However, we purposely removed all remaining absorbable sutures on the 5-7 day follow-up visit. In Part II, we will allow the absorbable sutures to dissolve on their own. We will again assess long term cosmetic outcomes, as well parental satisfaction, and short and long-term complication rates at 3 months.
A composition of matter comprising a capsule or tablet, sized and designed for oral ingestion by a human, containing the  3 R- 3 ′R stercoisorner of zeaxanthin. The  3 R- 3 ′R stereoisomer of zeaxanthin constitutes at least about 90 percent of all zeaxanthin, while S-S and S-R stereoisomers constitute less than about 10 percent of all zeaxanthin in the capsule or tablet. The capsule or tablet contains a sufficient quantity of the  3 R- 3 ′R stereoisomer of zeaxanthin to cause a detectable increase in zeaxanthin concentration in retinal tissue, or at least about 0.5 milligrams. It can be concentrated into an oily fluid or prepared in a microencapsulated granular formulation. The zeaxanthin can also be added to various types of foods, such as margarine, dairy products, syrup, cookie dough, and meat preparations. When consumed, the zeaxanthin can help treat and prevent eye diseases including macular degeneration, a leading cause of vision loss.
A single, unilateral, subretinal injection of low dose (1E10 vg/eye) OPGx-001 is injected into two LCA5 adults (18 yo or above) in a sentinel fashion. A 30-day safety evaluation and data committee review and approval of continued dosing occurs. If additional dosing is recommended, a subsequent LCA5 adolescent (13-17) may be treated in a sentinel fashion, with a unilateral, subretinal injection of OPGx-001. A 30-day safety evaluation and data committee review and approval of continued dosing occurs. If additional dosing is recommended, two remaining adolescents (13-17) are eligible to be treated with a single, unilateral, subretinal injection of a low dose of OPGx-001. Total cohort size is 5 (2 adults and 3 adolescents).
Systems and methods are described for reducing the risk of overdosage from a patient activated implantable drug delivery system. In one embodiment, an implantable drug delivery system is configured to deliver a drug. An external activation unit is operable by a user to request activation of the implantable drug delivery system. The activation unit includes a controller to reject a request to activate the implantable drug delivery system prior to expiration of a lockout interval. The controller issues an activation signal to the implantable drug delivery system in response to a request received after expiration of the lockout interval. The controller restarts the lockout interval upon activating the drug delivery system.
Because of the severity of illness, the intensive care unit (ICU) is a setting where death is prevalent and where the majority of deaths involve decisions to withhold or withdraw life-sustaining therapies. There is substantial data to suggest that the quality of end-of-life care in the ICU is poor. Many patients die with moderate to severe pain, physicians are often unaware of patients' wishes regarding end-of-life care, and the care patients' receive is often not consistent with their treatment preferences. Our study aims to evaluate the effectiveness of a multi-faceted intervention to improve the quality of care for patients dying in, or shortly after a stay in, the ICU using a randomized controlled study of 12 hospitals. In addition we plan to examine the variability in, and predictors of, the quality of dying and end-of-life care in community hospital ICUs with the purpose of identifying the current quality of end-of-life care and the institutional, clinician, and patient factors associated with the quality of this care. We will evaluate the successful and unsuccessful components of the intervention and describe the institutional and clinician facilitators and barriers to the intervention's implementation, with a focus on identifying interventions to improve care for the dying at other sites.
In various implementations, a dental hygiene system may include a dental powder. The dental powder may include one or more compounds comprising calcium and/or magnesium. The dental powder may include one or more probiotics, in some implementations. The dental hygiene system (e.g., dental powder) may include bismuth subsalicylate. The dental hygiene system may include an applicator and the dental powder may be applied to the applicator. A user may use the dental hygiene system to improve a user's dental hygiene.
UNLABELLED: In the hepatis B virus (HBV) transgenic mouse model of chronic infection, the forkhead box protein A/hepatocyte nuclear factor 3 (Foxa/HNF3) family of pioneer transcription factors are required to support postnatal viral demethylation and subsequent HBV transcription and replication. Liver-specific Foxa-deficient mice with hepatic expression of only Foxa3 do not support HBV replication but display biliary epithelial hyperplasia with bridging fibrosis. However, liver-specific Foxa-deficient mice with hepatic expression of only Foxa1 or Foxa2 also successfully restrict viral transcription and replication but display only minimal alterations in liver physiology. These observations suggest that the level of Foxa activity, rather than the combination of specific Foxa genes, is a key determinant of HBV biosynthesis. Together, these findings suggest that targeting Foxa activity could lead to HBV DNA methylation and transcriptional inactivation, resulting in the resolution of chronic HBV infections that are responsible for approximately one million deaths annually worldwide.
IMPORTANCE: The current absence of curative therapies capable of resolving chronic hepatis B virus (HBV) infection is a major clinical problem associated with considerable morbidity and mortality. The small viral genome limits molecular targets for drug development, suggesting that the identification of cellular factors essential for HBV biosynthesis may represent alternative targets for therapeutic intervention. Genetic Foxa deficiency in the neonatal liver of HBV transgenic mice leads to the transcriptional silencing of viral DNA by CpG methylation without affecting viability or displaying an obvious phenotype. Therefore, limiting liver Foxa activity therapeutically may lead to the methylation of viral covalently closed circular DNA (cccDNA), resulting in its transcriptional silencing and ultimately the resolution of chronic HBV infection.